Actavis PLC (ACT): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.1%. By the end of trading, Actavis rose $7.21 (4.2%) to $177.11 on heavy volume. Throughout the day, 2,294,830 shares of Actavis exchanged hands as compared to its average daily volume of 1,240,400 shares. The stock ranged in a price between $169.50-$177.79 after having opened the day at $170.08 as compared to the previous trading day's close of $169.90. Other companies within the Health Care sector that increased today were: IMRIS ( IMRS), up 40.4%, NuPathe ( PATH), up 35.6%, Oramed Pharmaceuticals ( ORMP), up 31.3% and ARCA biopharma ( ABIO), up 25.6%.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $29.2 billion and is part of the drugs industry. Shares are up 1.1% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Actavis a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

On the negative front, Mast Therapeutics ( MSTX), down 20.9%, AxoGen ( AXGN), down 13.1%, Prosensa Holding N.V ( RNA), down 11.4% and DARA Biosciences ( DARA), down 10.2% , were all laggards within the health care sector with Questcor Pharmaceuticals ( QCOR) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Icahn Bets on Allergan's Brett Saunders in Post-Pfizer Era

What Bill Ackman's Voice Could Mean for the Valeant Board Room

What Bill Ackman's Voice Could Mean for the Valeant Board Room

Jim Cramer: There’s No Way We’ll See More Railroad M&A

Federal Reserve to Reassess Global Risks in Minutes on Wednesday

Can Allergan-Pfizer Survive Treasury's New Crackdown on Inversions?